Knockdown of DNA methyltransferase‑1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells

Zhou,Wenwen; Chen,Huying; Hong,Xiuli; Niu,Xiaoqing; Lu,Quanyi

doi:10.3892/ol.2014.2481

Knockdown of DNA methyltransferase‑1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells

Authors:
- Wenwen Zhou
- Huying Chen
- Xiuli Hong
- Xiaoqing Niu
- Quanyi Lu
View Affiliations

Affiliations: Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361000, P.R. China
Published online on: August 26, 2014 https://doi.org/10.3892/ol.2014.2481
Pages: 2130-2134

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA methyltransferases (including DNMT1, DNMT3A and DNMT3B), catalyze the transfer of methyl groups from S‑adenosyl‑l‑methionine to cytosine position 5; this methylation in promoter regions silences gene expression. In addition, DNMT1 plays a critical role in the maintenance of genomic DNA methylation during DNA replication. In the present study, silencing of DNMT1 with siRNA was performed in RPMI‑8226 human multiple myeloma (MM) cells, and the impact on gene methylation status and proliferation of the cells was analyzed. Upon DNMT1 downregulation, proliferation decreased significantly compared with that in the control, non‑transfected cells. The expression of B‑cell lymphoma 2 and nuclear factor κB proteins was also significantly reduced. Furthermore, nested methylation‑specific polymerase chain reaction revealed that methylation of the tumor suppressor genes, suppressor of cytokine signaling 1 and p16, was significantly reduced upon DNMT1 knockdown. Our results suggest that DNMT1 silencing may be a promising strategy to consider during development of novel MM treatment strategies.

View Figures

View References

1	Benjamin M, Reddy S and Brawley OW: Myeloma and race: a review of the literature. Cancer Metastasis Rev. 22:87–93. 2003.
2	Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011.
3	Richardson PG, Barlogie B, Berenson J, et al: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 106:2977–2981. 2005.
4	Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 116:679–686. 2010.
5	Chen T and Li E: Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol. 60:55–89. 2004.
6	Robertson KD: DNA methylation and human disease. Nat Rev Genet. 6:597–610. 2005.
7	Belinsky SA, Nikula KJ, Baylin SB, et al: A microassay for measuring cytosine DNA methyltransferase activity during tumor progression. Toxicol Lett. 82–83:335–340. 1995.
8	Vertino PM, Yen RW, Gao J and Baylin SB: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol. 16:4555–4565. 1996.
9	Ng MH, Chung YF, Lo KW, et al: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 89:2500–2506. 1997.
10	Mateos MV, García-Sanz R, Lopez-Perez R, et al: Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol. 118:1034–1040. 2002.
11	Chim CS, Liang R, Fung TK, et al: Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 60:664–669. 2007.
12	Ng MH, Lau KM, Wong WS, et al: Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. Br J Haematol. 123:637–645. 2003.
13	Galm O, Yoshikawa H, Esteller M, et al: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 101:2784–2788. 2003.
14	Galm O, Wilop S, Reichelt J, et al: DNA methylation changes in multiple myeloma. Leukemia. 18:1687–1692. 2004.
15	Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6:107–116. 2006.
16	Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet. 9:2395–2402. 2000.
17	Szyf M, Pakneshan P and Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol. 68:1187–1197. 2004.
18	Xu M, Gao J, Du YQ, et al: Reduction of pancreatic cancer cell viability and induction of apoptosis mediated by siRNA targeting DNMT1 through suppression of total DNA methyltransferase activity. Mol Med Rep. 3:699–704. 2010.
19	Milutinovic S, Knox JD and Szyf M: DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). J Biol Chem. 275:6353–6359. 2000.
20	Ghoshal K and Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 43:395–422. 2007.
21	Auerkari EI: Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol. 42:5–13. 2006.
22	Chim CS, Fung TK and Liang R: Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia. 17:2533–2535. 2003.
23	Komazaki T, Nagai H, Emi M, et al: Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol. 34:191–194. 2004.
24	Jost E, Gezer D, Wilop S, et al: Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett. 281:24–31. 2009.
25	Tshuikina M, Jernberg-Wiklund H, Nilsson K, et al: Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp Hematol. 36:24–31. 2008.
26	Lin RK, Hsu HS, Chang JW, et al: Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer. 55:205–213. 2007.
27	Ahluwalia A, Hurteau JA, Bigsby RM, et al: DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 82:299–304. 2001.
28	Robert MF, Morin S, Beaulieu N, et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 33:61–65. 2003.
29	Ting AH, Schuebel KE, Herman JG, et al: Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet. 37:906–910. 2005.
30	Giuliani N, Colla S, Sala R, et al: Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 100:4615–4621. 2002.
31	Xiao W, Hodge DR, Wang L, et al: NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther. 3:1007–1017. 2004.
32	Conticello C, Giuffrida R, Adamo L, et al: NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res. 35:52–60. 2004.
33	Kannaiyan R, Hay HS, Rajendran P, et al: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011.
34	Baliga BC and Kumar S: Role of Bcl-2 family of proteins in malignancy. Hematol Oncol. 20:63–74. 2002.
35	Chen Q, Ray S, Hussein MA, et al: Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma. 44:1209–1214. 2003.